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A R T I C L E   I N F O A B S T R A C T 
Three Dimensional (3D) printing within the pharmaceutical industry is rapidly 
developing and current trends within drug development include the 3D printing of 
oral dosage forms, implants, hydrogels and topical drug delivery systems. 3D 
printed dosage forms can be used to treat a range of conditions varying from 
cardiovascular disease to recovery from orthopaedic surgery and the prevention of 
infection. Compared to traditional manufacturing methods, 3D printing allows the 
precise spatial control and deposition of material as layers. This results in a large 
degree of printing flexibility and means that a variety of complex designs can be 
printed accurately. By controlling factors such as the type of polymer, drug load and 
surface area a variety of controlled release dosage formulations can be produced and 
application in personalised medicine holds promise. Multiple release oral dosage 
forms can also be printed as well as those containing more than one Active 
Pharmaceutical Ingredient (API) which addresses polypharmacy and should aid 
medical treatment. This review studies recent trends in 3D printing and drug 
development, and current drawbacks are examined to evaluate the future potential 
to manufacture dosage forms. 
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INTRODUCTION 
3D printing is an Additive Manufacturing process 
producing a 3D object which often exhibits complex 
structures which may be difficult or impossible to 
assemble in a single piece with conventional 
manufacturing techniques. A model is made using 
Computer Aided Design (CAD) and the object is 
printed by deposition of material in the X, Y and Z 
planes (Ventola, 2014; Nale and Kalbande, 2015; Feng 
et al., 2018). Materials used in this process include 
powders, plastics and metals  (Ventola, 2014), and 3D 
printing requires processes such as printing-based 
inkjet systems, nozzle-based deposition systems and 
laser-based writing systems (Goole and Amighi, 
2016). 3D printing was first established by Charles 
Hull in 1986 with the patency of Stereolithography 
SLA (Hull, 1986). Since then it has developed and is 
now used within many fields including the 
automotive industry, aerospace, the military (Gebler 
et al., 2014; Gross et al., 2014; Nale and Kalbande, 
2015) houseware production and construction 
(Berman, 2012). Within healthcare 3D printing 
produces tissue, anatomical models and organs (Liaw 
and Guvendiren, 2017; Berman, 2012; Nale and 
Kalbande, 2015; Feng et al., 2018). The use of 3D 
printing within drug development has dramatically 
increased (Trenfield et al., 2018) over the past thirty 
years and now produces tablets, caplets, Orally 
Disintegrating Tablets (ODTS), implants, hydrogels, 
and topical delivery systems (Liaw and Guvendiren, 
2017; Trenfield et al., 2018). 
Review 
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Currently 3D printing within drug development is 
centred on oral dosage forms. Orphan drug tablets can 
be manufactured as small batches on-demand and at 
low cost (Ciurczak, 2016; Trenfield et al., 2018; Awad 
et al., 2018a). Tester tablets are used by 
pharmaceutical companies to calibrate dissolution 
testers for immediate and continuous release dosage 
forms (Ciurczak, 2016). 3D printing enables these 
tablets to be produced in small batches as required 
(Ciurczak, 2016; Hsiao et al., 2018). This reduces waste 
and improves tablet reproducibility, thus increasing 
the reliability of conclusions drawn from dissolution 
testing (Ciurczak, 2016; Awad et al., 2018b). 3D 
printing can produce tablets that provide complex 
release profiles including delayed release and 
multiple-release dosage forms. Tablets containing 
more than one API can also be manufactured 
(Ventola, 2014; Maroni et al., 2017; Kadry et al., 2018; 
Goyanes et al., 2017a; Genina et al., 2017; Trenfield et 
al., 2018; Nale and Kalbande, 2015; Korte and 
Quodbach, 2018) which can decrease polypharmacy 
and increase medication efficacy. The production of 
medication by 3D printing may help to increase API 
solubility by producing amorphous forms. It may also 
be possible to limit the degradation of biologicals and 
prevent drug incompatibilities (Goole and Amighi, 
2016) which should increase the bioavailability of the 
API and potentially lead to decreased dosing 
frequency, thus further improving patient 
compliance. 
3D printed hydrogels can be used as scaffolds for the 
growth of cells in tissue engineering (Placone et al., 
2017; Bertassoni et al., 2014), or implanted into the 
body to provide controlled API release (Gloria et al., 
2016). Research in this area is improving although the 
focus on drug development is not yet at its peak.  
Currently a large proportion of 3D printed implants 
also provide controlled API release, which is useful 
for the promotion of bone healing and the prevention 
of infection after orthopaedic surgery (Boetker et al., 
2016). Implants have also been 3D printed that release 
hormones for contraceptive purposes (Kempin et al., 
2017) therefore their application in medicine is 
increasing.  
The 3D printing of topical dosage forms is still in its 
infancy but there are promises for future 
development. In particular microneedles are of 
interest, as microneedle moulds and microneedles 
themselves (Economidou et al., 2018; Luzuriaga et al., 
2018) can be produced by 3D printing techniques. 
A major focus of 3D printing is the ability to produce 
personalised dosage forms on demand. This involves 
the tailoring of the medication dose to patient 
demographics (Trenfield et al., 2018; Ventola, 2014; 
Awad et al., 2018b, 2018a; Okwuosa et al., 2018) such 
as their genotype, age, weight, race, liver function, 
renal function and medical conditions (Ventola, 2014) 
This should improve medication efficacy and reduce 
adverse drug reactions, which should increase patient 
compliance and therefore improve future medical 
treatment. 
Some research within the separate areas of oral dosage 
forms, hydrogels, implants and topical drug delivery 
has been completed. This has introduced 3D printing 
to drug development and manufacturing, however 
the information available is very specific to certain 
printers, APIs and processes. Consequently it is 
necessary to produce a systematic review using 
PRISMA guidelines (Moher et al., 2009) which groups 
all available research into set areas so that current 
trends can be established. It is hoped that quantitative 
analysis can also be completed so that a sound 
explanation of the current situation is obtained, areas 
that require improvement are highlighted and future 
research can be directed.  
Currently only one licensed 3D printed product exists 
called Spritam, containing the drug levetiracetam. It is 
an ODT (Petty et al., 2002; Hsiao et al., 2018) and is 
produced by the Drop-on-Powder (DOP) technique 
which is a binder jetting process that prints liquid 
binder onto thin layers of powder (Shirazi et al., 2015). 
Although an ODT provides rapid drug release and is 
easy to take (Fitzgerald, 2015), the formulation 
production relies on solvent evaporation which 
produces highly porous structures. Consequently it is 
difficult to produce controlled release preparations in 
this manner and not all APIs are suitable for use 
(Goole and Amighi, 2016). Therefore it is necessary to 
understand the current limitations within the area of 
3D printing and drug development. It would also be 
helpful to identify areas that require further 
development to aid future improvements and offer 
potential solutions in this area. 
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MATERIALS AND METHODS 
Although not conducting a true systematic review, 
PRISMA guidelines (Moher et al., 2009) were followed 
in order to ensure a transparent non-biased approach 
to literature collection. Web of Science, Google 
Scholar, Scopus and Science Direct search engines 
were chosen as they have access to a wide range of 
peer reviewed articles which should cover all current 
research within the area of 3D printing and drug 
development, and should reduce the likelihood of 
error in interpreted information. The initial search 
was completed using the same search terms of ‘3D 
printing’ and ‘drug development or drug 
manufacturing’ across all search engines so that the 
most relevant articles were found, and the search 
method was reliable. Where possible, the search was 
refined to select for the inclusion criteria of original 
research articles only and written in English. This 
enabled the selection of primary research in the form 
of articles, and ensured that current trends could be 
analysed.  
An adapted version of the PRISMA flow diagram, as 
shown below (Figure 1), was used to document the 
process of sorting articles so that the search method 
was transparent and will be repeatable in future to 
allow comparison. After the initial searching, the 
article search was further refined manually by 
exclusion based on title. Titles which did not contain 
the words ‘3D printing’ or other 3D printing processes 
such as Fused Deposition Modelling (FDM), Inkjet 
Printing (IP), Selective Laser Sintering (SLS), 
Stereolithography (SLA) and Drop-on-Demand 
(DOD) were excluded. Titles were also disregarded if 
they did not include anything to do with drug 
development or manufacturing, and if they stated that 
they were patents, citations or reviews so that only 
original research was analysed. Duplicates were then 
removed using the Mendeley referencing software to 
ensure accuracy. Full text articles were assessed for 
eligibility which involved studying the articles 
downloaded and looking for the emergence of current 
themes. Articles that were reviews, patents, citations 
or irrelevant, and had passed the initial screening 
because it was not clear from the title, were excluded. 
The article selection was narrowed down so that only 
those related to the review title were examined. For 
example, amongst the articles excluded were those 
concerning the 3D printing of tissues and 3D printing 
in general industry. In line with PRISMA guidelines, 
the quality of the articles was assessed so that only 
those deemed reputable were included. For example, 
acceptable articles were those that had been peer 
reviewed, clearly written and contained all of the 
relevant sections such as an introduction, methods, 
results, some form of analysis, discussion and 
conclusion, so that the research process could be 
followed. This enabled the collection of specific and 
accurate research that addressed the project 
objectives.  
 
Figure 1 - The PRISMA flow diagram which has been adapted to 
suit the research collected, demonstrating the method of searching 
and reasons for article exclusion. 
RESULTS AND DISCUSSION 
Interest in 3D printing within drug development has 
increased dramatically over the last thirty years, as 
shown by Figure 2. The general trend indicates that 
the number of articles published annually is at an all-
time high and as such research in this area is timely 
and of worth. This data was produced using the 
chosen search terms within Google Scholar only, 
without applying exclusion criteria so that a broad 
overview could be obtained.  
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Figure 2 - Number of published articles containing information on 
3D printing and drug development over the past thirty years 
On analysis of the number of articles found using each 
search engine it is clear that Google Scholar had access 
to the most research.   
Figure 3: Distribution of dosage form focus detailed in 
articles examined  
Initial identification of dosage form and 
administration route (Figure 3) demonstrated that the 
current main trends within 3D printing and drug 
development are oral dosage forms, hydrogels, 
implants and topical dosage forms. Most current 
research revolves around oral dosage forms. This is 
most likely as a result of the ease of manufacture, a 
large amount of published information and 
understanding and preferential selection as a dosage 
form as oral dosage forms are most widely accepted 
and used by patients as they are small, discreet and 
easy to take.  
On further analysis for article quality it was 
determined that quality articles addressed key areas 
and report information on API release, API loading 
and statistical analysis. Articles within the key theme 
areas were not consistent in doing this, as shown in 
Figure 4. Whilst articles regarding oral dosage forms 
contained the most data on API loading and release, 
research on implants provided better statistical 
analysis. 
Figure 4: A graph to show the percentage of articles within 
the three areas of oral dosage forms (n=37), hydrogels 
(n=12) and implants (n=12) which include data on API 
loading, API release and statistical analysis. Quality 
articles were considered to contain all of this information 
thus showing the area to be well researched.  
 Statistical analysis improves the reliability of 
conclusions made in published articles and the 
abundance of papers applying statistical tools to 
provide an evidence base for their conclusions need to 
be increased to improve the quality of research in this 
area. Very few research articles were found 
concerning topical drug delivery, therefore this was 
excluded from the graph because it would not be 
representative of the entire area. Data for hydrogels 
was also limited as most current research revolves 
around the process of printing and tissue engineering, 
with limited potential for API release. Problems with 
3D printing include API loading and release. For 
example Spritam is entirely dispersed in five seconds 
(Goole and Amighi, 2016), however oral dosage forms 
produced by SLA can take up to twenty hours for 
complete release (Martinez et al., 2017). These 
differences could be because 3D printing was not 
designed to build objects that are broken down.  
A wide variety of APIs have been 3D printed, as 
shown in Table 1. Oral delivery systems tend to 
include APIs for medical conditions such as 
cardiovascular disease and diabetes whereas implants 
tend to be used to prevent infection so contain 
antibiotics, or used as hormonal contraceptives. Some 
articles do not focus on the therapeutic outcome, but 
examine the ability of certain 3D printers to produce 
set formulations. Therefore the API is chosen for its 
ease of printing and desirable characteristics such as 
good water solubility and high extrusion 
temperatures so that degradation is avoided. 
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Table 1. A wide range of APIs were studied within the research 
articles reviewed. Paracetamol was used most commonly, in fifteen 
papers. Theophylline was the next most common, found in seven 
papers, whilst the majority of the APIs were found in one or two 
papers. 
API No. of 
articles 
API No. of 
articles 
4-ASA 2 Ibuprofen 2 
5-ASA 2 Indomethacin 2 
Aripiprazole 1 Isoniazid 2 
Aspirin 1 Metformin 1 
Atenolol 1 Methotrexate 2 
Budesonide  2 Naproxen 2 
Caffeine 2 Nifedipine 1 
Captopril 2 Nitrofurantoin 4 
Celecoxib 1 Oestrogen 1 
Cidofovir 1 Paclitaxel 1 
Curcumin 1 Pantoprazole 1 
Deflazacort 1 Paracetamol 14 
Dexamethasone 1 Pravastatin 1 
Diclofenac 1 Prednisolone 2 
Dipyridamole 4 Progesterone 1 
Fenofibrate 1 Quinine 1 
Fluorescein 1 Ramipril 2 
Gentamicin 1 Rifampicin 2 
Glipizide 1 Ropinirole 1 
Guaifenesin 1 Silver 1 
Haloperidol 2 T Cells 1 
Hydrochlorothiazide 2 Theophylline 7 
The main 3D printing techniques used in drug 
development are FDM, SLA, SLS, IP, and Injection 
Moulding (IM) (Tagami et al., 2017; Hsiao et al., 2018). 
3D printing is useful because improvements can be 
made instantly by adjustment to the CAD file (Gupta 
et al., 2015). Commercial 3D printers have a higher 
resolution than traditional manufacturing methods 
and therefore allow greater customisation of infill 
percentages and geometries to tailor drug release 
rates (Weisman et al., 2015; Arafat et al., 2018b). 
Current research is aimed at personalised on-demand 
medication printing to reduce waste and mileage 
(Kurzrock and Stewart, 2016; Awad et al., 2018b). 
Importantly, the digital file of a vaccine for a global 
endemic could be sent around the world and 
administered in a short time (Kietzmann et al., 2015) 
thus saving lives.  
SLA uses a laser to photopolymerise liquid resin 
forming a cross-linked polymer matrix, used mainly 
for tissue engineering and scaffolding. Release rate is 
controlled by the polymer. The number of photo-
crosslinkable polymers is increasing, and include 
polyethylene glycol diacrylate (PEGDA) and 
polyhydroxyethylmethacrylate (pHEMA). SLA can 
print thermally labile APIs at a higher resolution and 
complexity than IP (Martinez et al., 2017; Wang et al., 
2017; Economidou et al., 2018; Martinez et al., 2018), 
however a photo-initiator is often required such as 
riboflavin and triethanolamine. They are more 
biocompatible than others such as Irgacure (Martinez 
et al., 2017), however toxicity is still an issue (Martinez 
et al., 2017; Hsiao et al., 2018; Feng et al., 2018) thus 
limiting their use.   
IP involves the deposition of droplets containing the 
API in solution. The dose depends on the drop size 
printed and control systems are being developed to 
predict the dissolution profile (Içten et al., 2015; 
Hirshfield et al., 2014). IP allows rapid 
polymerisation, co-deposition of multiple inks at high 
resolution and controlled distribution providing 
accurate dosing which is useful for potent drugs 
(Kyobula et al., 2017; Han et al., 2016; Pietrzak et al., 
2015). However hollow structures cannot be printed, 
unlike FDM (Goyanes et al., 2014; Clark et al., 2017), 
leading to fewer printable geometries. Printing poorly 
water-soluble APIs is difficult. It is possible to mix 
them with polymers as a dispersion, solution or 
emulsion although this is difficult to scale up and high 
API to polymer ratios and temperatures cause 
solidification. These parameters alongside the 
viscosity of the polymer, pH, print speed and surface 
tension need to be tailored for optimal printing (Han 
et al., 2016; Wickstrm et al., 2017; Hirshfield et al., 
2014; Hsu et al., 2013; Pietrzak et al., 2015; Clark et al., 
2017).  
SLS is a solvent free, one-step process. Temperature 
and laser scanning speed control the printed product. 
Objects produced are of a higher precision than FDM, 
however high energy lasers can degrade the API 
therefore SLS tends to be limited to tissue engineering 
or printing drug delivery devices where the API is 
loaded after printing.  However,  tablets were 
produced containing paracetamol (Fina et al., 2017, 
2018b, 2018a), proving that printing oral dosage forms 
is possible and requires future development. 
Microspheres can also be printed which increases API 
solubility and reduces degradation (Wang et al., 2015). 
FDM prints polymer filaments and is useful because 
it is cheap and versatile (Melocchi et al., 2016; Goyanes 
et al., 2016b, 2014; Skowyra et al., 2015; Goyanes et al., 
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2017a; Okwuosa et al., 2018). Intricate designs can be 
produced making FDM good for rapid prototyping 
where a representation of the item is created before it 
is mass produced, thus reducing development time 
and cost (Awad et al., 2018a; Melocchi et al., 2016; 
Glatzel et al., 2016; Feng et al., 2018; Okwuosa et al., 
2018). Resolution is limited to a 0.4 mm tip  (Melocchi 
et al., 2016; Goyanes et al., 2015c; Sadia et al., 2016) but 
granules, pellets, implants and transmucosal films can 
be printed (Goyanes et al., 2015c; Awad et al., 2018a). 
Polymers can be loaded by swelling in a solution of 
the API. This reduces degradation and cost but 
produces low drug loads, often less than 3%, so is 
most appropriate for potent drugs (Goyanes et al., 
2014; Tagami et al., 2017; Kempin et al., 2017; Goyanes 
et al., 2015b, 2016b). FDM is often combined with Hot 
Melt Extrusion (HME) which enables a higher drug 
loading (Smith et al., 2018; Yang et al., 2018; Melocchi 
et al., 2016; Goyanes et al., 2016b, 2015c, 2015a; Zhang 
et al., 2017a; Goyanes et al., 2015b; Khorasani et al., 
2016) but is costly and may produce rough filaments 
that cause nozzle blockages, although this is 
compensated by the ease of storage and reduced 
waste (Skowyra et al., 2015; Zhang et al., 2017a; 
Nasereddin et al., 2018). Current research is also 
developing a method to screen the mechanical 
properties of hot-melt extruded filaments based on 
flexibility, to predetermine FDM suitability 
(Nasereddin et al., 2018). One major drawback is that 
extrusion temperatures can degrade drugs and 
excipients (Goyanes et al., 2014; Gupta et al., 2015; 
Genina et al., 2017; Okwuosa et al., 2018; Melocchi et 
al., 2018; Whyman et al., 2018; Kollamaram et al., 2018; 
Kempin et al., 2018; Goyanes et al., 2015a), as seen 
with 5-aminosalicylic acid (5-ASA) and curcumin. 
However this can be limited by increasing the print 
speed, choosing polymers with low extrusion 
temperatures (Kollamaram et al., 2018; Tagami et al., 
2017; Boetker et al., 2016; Kempin et al., 2018; Goyanes 
et al., 2015a) and using carriers (Andersen et al., 2013). 
Higher temperatures cause reduced viscosity 
therefore better flow from the nozzle although a 
sufficient viscosity is needed to form a polymer strand 
for deposition (Kempin et al., 2017; Varan et al., 2017; 
Goyanes et al., 2015b; Li et al., 2018). A high breaking 
stress and long breaking distance is necessary for 
optimum printing (Zhang et al., 2017a; Goyanes et al., 
2015a; Verstraete et al., 2018). Polyvinyl alcohol (PVA) 
and acrylonitrile butadiene have the best stiffness, 
toughness and melt velocity for printing. Drugs such 
as quinine often act as plasticisers and decrease the 
glass transition temperature which can promote 
degradation (Kempin et al., 2017; Varan et al., 2017; 
Goyanes et al., 2015b; Li et al., 2018) although printing 
can be done at room temperature which avoids 
stability problems (Khaled et al., 2015b, 2014). 
Dual syringes can print complex materials accurately 
and affordably (Bootsma et al., 2017). The type and 
amount of plasticiser must be adjusted to enable the 
extrusion of higher drug loads and to improve 
filament quality (Melocchi et al., 2016; Goyanes et al., 
2015c, 2015d, 2017a).  
API release rate is dictated by a combination of API 
crystallinity, polymer crystallinity, API loading, 
extrusion temperature and solubility in release 
medium (Genina et al., 2016). It is important that drug 
dissolution reaches the FDA threshold (Jamróz et al., 
2017), which it has done for most of the research 
available. Release is mostly dictated by an erosion-
diffusion process. As the polymer disintegrates the 
API diffuses out therefore polymer choice is 
important (Tagami et al., 2017; Beck et al., 2017; 
Skowyra et al., 2015; Li et al., 2018; Sadia et al., 2018; 
Melocchi et al., 2015; Yang et al., 2018; Zhang et al., 
2017a; Khaled et al., 2015b; Goyanes et al., 2015d, 
2015a, 2015c, 2015b, 2016b, 2014, 2017a). APIs with a 
higher water solubility exhibit faster release (Goyanes 
et al., 2016b; Water et al., 2015; Genina et al., 2016) as 
disintegration depends on hydration, swelling and 
polymer break up. Barrier thickness and the physio-
chemical properties of the polymer affect lag time. The 
use of water soluble polymers such as PVA improve 
dissolution enabling faster API release therefore tend 
to produce immediate release formulations (Melocchi 
et al., 2016; Verstraete et al., 2018; Jamróz et al., 2017; 
Skowyra et al., 2015; Okwuosa et al., 2016; Yang et al., 
2018). For example immediate API release within 25 
minutes can be obtained using hydroxypropyl 
cellulose (HPC) and Eudragit E to print tablets 
(Melocchi et al., 2016; Khaled et al., 2015a; Goyanes et 
al., 2015a, 2015b). Polymers that produce slow release 
are more limited, for example to PVA, polyamide 
(PA), ethylene vinyl acetate (EVA), polycaprolactone 
(PCL), methacrylic and cellulose polymers. 
Unfortunately they often have a low drug loading 
(below 30%) and require a plasticiser. High polymer 
concentration increases wettability and water uptake 
  https://doi.org/10.5920/bjpharm.2018.XX 
Hampshire and Russell (2018) BJPharm, Vol(No), pp  7 
so increases swelling and gel barrier formation 
(Melocchi et al., 2016; Khaled et al., 2015b; Goyanes et 
al., 2015a, 2015b) thus delaying API release. Kempin 
et al., 2017 found that PCL provided the fastest rate of 
API release, when compared to Eudragit RS and EC 
as Eudragit is less prone to swelling (Kempin et al., 
2017). An increase in the molecular weight of the 
polymer was also shown to prolong drug release. 
EVA copolymers vary in terms of vinyl acetate 
content, melting index and flexural modulus. Lower 
melt index causes greater swelling and makes 
printing more difficult; the flexural modulus is lower 
for EVA than PCL. If the melt index is too high 
droplets are not viscous enough to form. Melt index 
increases with vinyl acetate content and decreased 
polymer molecular weight (Genina et al., 2016). The 
device surface, size and cellular penetration is 
dictated by the polymer used, where reducing the size 
increases the surface area and bioavailability (Varan 
et al., 2017; Zhao et al., 2018). 
 A wide variety of polymers are used for 3D printing, 
as shown in Table 2. Selection of the polymer is a 
compromise between release properties, mechanical 
properties, degradation profile and processing (Water 
et al., 2015). Viscosity, shear thinning behaviour, 
elastic modulus and yield strength are important 
(Sommer et al., 2017). Polymer elasticity and 
brittleness dictate outflow from the nozzle and 
therefore the reproducibility of printing (Jamróz et al., 
2017; Verstraete et al., 2018). Increasing polymer 
concentration increases viscosity which can make 
printing harder, however it has also been shown to 
increase elasticity. Sufficient viscosity is necessary to 
maintain structural integrity after printing (Ersumo et 
al., 2016; Abbadessa et al., 2017; Sayyar et al., 2017). 
Polylactic acid (PLA) and PCL are used for medical 
devices whereas PVA is used for oral dosage forms 
(Goyanes et al., 2016b). Insoluble polymers include 
ethylcellulose and Eudragit RL; soluble polymers 
include polyethylene oxide and Kollicoat; enteric 
soluble polymers include Eudragit L and 
hydroxypropylmethylcellulose acetate succinate 
(HPMCAS), and swellable/ erodible polymers 
include hydrophilic cellulose derivatives, PVA and 
Soluplus  (Melocchi et al., 2016). Good mechanical 
properties, controlled API release, thermal stability 
and no cytotoxic effects have been shown for methyl 
methacrylate, butyl methacrylate, PLA, polyethylene 
glycol (PEG) and PEGDA photo-crosslinkable 
polymers for implant printing by SLA (Varan et al., 
2017). Thermoplastic polyurethanes printed with 
FDM and IM enable a greater drug loading without 
HME processing (Verstraete et al., 2018). PLA and 
PCL are often used as they are viscous when molten, 
easily deposited and solidify when cool (Andersen et 
al., 2013). A high correlation between the target and 
achieved dose has been achieved especially when 
using Eudragit (Pietrzak et al., 2015). 
Increasing the surface area to volume ratio increases 
the API release rate because water uptake and 
diffusion is promoted (Sadia et al., 2018; Kempin et al., 
2017; Kyobula et al., 2017; Sommer et al., 2017; Tagami 
et al., 2018; Solanki et al., 2018; Pietrzak et al., 2015; 
Goyanes et al., 2015d; Skowyra et al., 2015). Therefore 
control of geometry (Genina et al., 2016; Varan et al., 
2017) and porosity is important, with higher porosity 
often caused by low drug loads (Costa et al., 2015; Min 
et al., 2015; Ersumo et al., 2016; Sayyar et al., 2017), 
however this also leads to greater weight variation 
(Goyanes et al., 2016b; Fina et al., 2017; Verstraete et 
al., 2018). Channelling agents enhance permeability 
(Melocchi et al., 2016; Beck et al., 2017; Sadia et al., 
2018), by increasing porosity which increases drug 
release (Melocchi et al., 2016; Beck et al., 2017; Solanki 
et al., 2018; Sadia et al., 2018; Arafat et al., 2018b). 
However API solubility and loading was shown to 
have a greater impact on API release than porosity for 
PVA printed caplets (Goyanes et al., 2016b; Pietrzak et 
al., 2015; Hsu et al., 2013). Also surface area was not 
shown to effect curcumin release from a PVA filament 
(Tagami et al., 2017) thus proving that all factors 
including API solubility and polymer type (Kyobula 
et al., 2017) must be considered when predicting API 
release.  
In most cases a higher infill percentage causes slower 
API release (Beck et al., 2017; Kyobula et al., 2017; 
Zhang et al., 2017a; Li et al., 2018; Hsu et al., 2013; 
Tagami et al., 2017; Genina et al., 2016; Kempin et al., 
2017; Water et al., 2015; Goyanes et al., 2015a, 2017a; 
Melocchi et al., 2015), which may be because the API 
is present in its crystalline state (Kyobula et al., 2017) 
or because structures are less porous with a lower 
surface area (Zhang et al., 2017a; Solanki et al., 2018). 
Although increasing the API load increases filament 
hardness which may limit printing. Therefore it is 
possible to control API release by controlling infill 
percentage. It is also important to select the best 
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solvent to optimise drug loading, and use fillers to aid 
flow if necessary, such as tri-calcium phosphate 
(Goyanes et al., 2015a; Sadia et al., 2016). 
Table 2. A wide range of polymers were used within the 3D 
printing processes of FDM, IM, IP, DOD, SLA and SLS in the 
physical form of a filament, waxy solid, flakes, powder, neat, 
lyophilised, beads, liquid, viscous liquid, paste, crystals, solid, 
sheet, rod, resin, pellets or granules. The most common printing 
application is FDM and the most widely used polymers are 
HPMC and PCL.  
Polymer Physical Form  Printing 
Application 
Acrylonitrile 
butadiene styrene 
(ABS) 
Filament FDM, IM 
Beeswax Waxy Solid IP 
Chitosan Flakes/ 
powder 
FDM 
Ethyl cellulose Filament/ 
powder/neat 
FDM 
High impact 
polystyrene (HIPS) 
Filament FDM 
Hydroxyethylcellulos
e (HEC) 
Filament FDM 
Hydroxypropyl 
cellulose (HPC) 
Powder/ 
filament 
FDM, IM 
Hydroxypropyl 
methyl cellulose 
(HPMC) 
Powder/ 
filament 
FDM, 
IM,DOD 
Hydroxypropylmeth
ylcellulose acetate 
succinate (HPMCAS) 
Powder/ 
filament 
FDM, IM 
Keratin Lyophilised SLA 
Methacrylic acid 
(Methyl methacrylate 
copolymer) 
Filament FDM 
Microcrystalline 
cellulose (MCC) 
Powder/ 
filament 
FDM 
Poly (ethylene vinyl 
acetate) 
Filament/ 
beads 
FDM 
Poly(acrylic acid) 
(PAA) 
Powder FDM 
Poly(D,L-lactide-co-
glycolide) (PLGA) 
Liquid/ 
viscous 
liquid/paste/ 
filament 
FDM, IP 
Poly(ethylene glycol) 
dimethacrylate 
(PEGDMA) 
Powder/resin
/solution 
SLA 
Poly(ethylene oxide) 
(PEO) 
Filament/ 
powder 
FDM 
Poly(ethylene-co-
vinyl acetate)  
Beads/ 
filament 
FDM 
Poly(L-lactide) 
(PLLA) 
Filament/ 
powder 
FDM 
Poly(methacrylic 
acid-co-methyl 
methacrylate) 
 
FDM 
Poly(methyl 
methacrylate) 
(PMMA) 
Neat/powder
/crystalline/ 
resin 
FDM 
Poly(N-(2-
hydroxypropyl) 
methacrylamide-
mono/dilactate 
(pHPMAlac) 
Powder SLA 
Poly(N-
isopropylacrylamide) 
(PNIPAM) 
Crystals/cryst
alline powder 
IP 
Poly3-
hydroxybutyrate-co-
3-hydroxyhexanoate 
(PHBHHx) 
Powder FDM  
Polyamide (PA) Powder SLS, IM 
Polycaprolactam  Powder FDM, IM 
Polycaprolactone 
(PCL) 
Flakes/pellets
/granules/ 
Filament 
FDM, IP, 
SLA 
Polycarbonate (PC) Film/pellets SLS, IM 
Polyether ether 
ketone (PEEK) 
Powder/ 
crystals/ 
filament 
SLS,FDM 
Polyethyene glycol 
diacrylate (PEGDA) 
Solid SLA 
Polyethylene glycol 
(PEG) 
Liquid IP,SLA 
Polyethylene glycol 
diacrylate (PEGDA) 
Solid SLA, IP 
Polyethylenimine 
(PEI) 
Viscous liquid IP 
Polylactic acid (PLA) Filament FDM, IM 
Polyphenylsulfone 
(PPSF) 
Sheet/rod/ 
filament 
FDM 
Polyvinyl alcohol 
(PVA) 
Powder/ 
crystals/ 
filament 
FDM, IM 
Polyvinyl alcohol-
polythylene glycol 
graft copoymer 
(Kollicoat IR) 
Filament FDM,SLS 
Polyvinyl 
caprolactam-
polyvinyl acetate-
polyetylene glycol 
graft copolymer 
(Eudragit L, RL, RL-
PO) 
Filament FDM 
Polyvinylpyrrolidone 
(PVP) 
Powder/cryst
als/filament 
DOD,FDM 
Sodium Alginate Solid IP 
Sodium starch 
glycolate (SSG) 
Powder FDM 
Polyvinyl 
caprolactam–
polyvinyl acetate–
polyethylene glycol 
graft copolymer 
(Soluplus)                    
               
Filament 
                   
FDM 
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It is generally preferred that APIs are in their 
crystalline form because of lower energy states and 
thermodynamic favourability. However this makes 
the API less soluble, therefore lipid-based 
formulations such as emulsions are printed to increase 
the solubility of APIs with a low water solubility, as 
shown with celecoxib (Içten et al., 2017). Poorly 
soluble APIs such as nitrofurantoin and aripiprazole 
can be incorporated into a water soluble polymer to 
improve bioavailability (Sandler et al., 2014; Jamróz et 
al., 2017). Nanoparticles can be printed by IP, FDM 
and SLS which also improves the delivery of poorly 
water soluble APIs and unstable compounds thus 
potentially reintroducing previously discarded APIs. 
Greater control of API release is enabled (Wickstrm et 
al., 2017; Yuksel and Cullinan, 2016; Beck et al., 2017) 
however this is yet to be studied in humans. 
As 3D printing was not originally designed for drug 
manufacture, toxic excipients and the limited number 
of polymers available is a challenge (Feng et al., 2018; 
Melocchi et al., 2016; Clark et al., 2017; Gupta et al., 
2015; Kyobula et al., 2017; Sadia et al., 2016; Okwuosa 
et al., 2016). Polymer degradation can also occur as in 
the case of Eudragit RL, which lead to API 
degradation by lowering the melting point (Pietrzak 
et al., 2015; Sadia et al., 2016), proving that control of 
printing temperature is important. Printable edible 
inks are being researched, such as seaweed full of 
cellulose. However these inks often require additives 
to improve rheological properties for printing, 
therefore more need to be developed before the 3D 
printing of ingestible dosage forms is a success (Feng 
et al., 2018). 
Research on human acceptability of 3D printed 
medicines has been completed  (Goyanes et al., 2017b), 
however in vivo research regarding API release and 
pharmacokinetics has only been completed in rats for 
a tiny number of oral dosage forms (Genina et al., 
2017; Goyanes et al., 2018; Arafat et al., 2018a) and two 
types of implants (Tappa et al., 2017; Min et al., 2015). 
The flexibility of 3D printing has also been 
demonstrated with the ability to titrate the dose of 
warfarin, a narrow therapeutic index drug, both in 
vitro and in vivo thus allowing accurate medication 
dosing (Arafat et al., 2018a). Even though in vitro 
results look promising, it is difficult to determine 
efficacy in man. Many more in vivo studies need to be 
undertaken before the utility of 3D printed 
formulations can be established. It is also argued that 
the 3D printing of medication has the potential to 
increase illegal and unregulated medication printing 
(Yampolskiy et al., 2016; Kietzmann et al., 2015) 
therefore strict regulations need to be considered 
before the 3D printing of medication can be 
commercialised. 
Oral Dosage Forms 
Tablets, caplets and ODTs can be 3D printed, as well 
as multiple tablet shapes which can’t be produced 
using traditional methods (Awad et al., 2018a; 
Goyanes et al., 2015c; Khaled et al., 2015a). 
Tetrahedron shapes have a long stomach residence 
time and produce controlled release over ten hours 
(Goyanes et al., 2015c). Tablets printed as a torus 
shape were favoured in a randomised study by 
Goyanes et al., 2017b, proving the importance of being 
able to print varying shapes to improve patient 
compliance. Desktop 3D printers using room 
temperature extrusion can print tablets with 
immediate and slow release parts (Khaled et al., 2014; 
Awad et al., 2018a; Kempin et al., 2018), thus 
potentially making it possible to print medication at 
home. Controlling the internal structure also modifies 
release profiles (Goyanes et al., 2017a; Zhang et al., 
2017a). For example a honeycomb architecture 
controls API release by tailoring the cell size, which 
influences the surface area (Tagami et al., 2017; 
Solanki et al., 2018) without needing to alter the 
formulation, thus saving money and time. Similarly 
‘gaplets’ have been produced which contain a rigid 
multi-block design with fixed gaps and allow 
immediate API release (Arafat et al., 2018b). 
Channelled tablets facilitate accelerated release and 
shorter channels cause faster dissolution therefore the 
number, width and length of channels can be tailored 
to the required release. However this approach is 
better suited to non-swelling systems as swelling can 
cause channel closure (Sadia et al., 2018).  
Low flow rates used in FDM produce tablets with a 
lower density and infill percentage (Tagami et al., 
2017), therefore showing faster API release than 
tablets printed by IM (Fina et al., 2017; Verstraete et 
al., 2018; Korte and Quodbach, 2018; Goyanes et al., 
2016b). Low density tablets can enable gastro-
retentive medication which increases the 
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bioavailability for APIs absorbed in the stomach 
(Tagami et al., 2017; Li et al., 2018).  
Tablets can be printed and then enteric coated to allow 
modified release. This can be done in one step using a 
dual nozzle FDM printer with separate polymers for 
the core, such as polyvinylpyrrolidone (PVP), and the 
coat, such as methacrylic acid copolymer (Korte and 
Quodbach, 2018; Whyman et al., 2018; Nasereddin et 
al., 2018). However nozzle clogging is an issue as 
material adheres to the inner wall due to a difference 
in nozzle temperatures (Whyman et al., 2018; 
Nasereddin et al., 2018; Goyanes et al., 2015b). Enteric 
coated tablets can show pH-dependent release in the 
small intestine caused by carboxylic acid groups. Shell 
thickness also dictates API release, with thicker and 
harder shells limiting release, regardless of the 
porosity (Zhang et al., 2017b; Okwuosa et al., 2018; 
Smith et al., 2018; Yang et al., 2018; Tagami et al., 2018; 
Goyanes et al., 2015b; Zhang et al., 2017a). Protection 
of the core from acidic medium is also enabled, but if 
the shell is not thick enough premature drug release 
occurs (Goyanes et al., 2015b).   
Multinozzle 3D printing by FDM and IM produces 
multilayer devices containing APIs within separate 
internal structures (Maroni et al., 2017; Melocchi et al., 
2015; Goyanes et al., 2015c). Pulsatile release is 
currently being researched for dietary supplements 
and other APIs (Melocchi et al., 2018). Two-pulse oral 
API delivery is enabled using pH-sensitive and time-
dependent release dictated by the type of polymer, 
wall thickness, API loading and solubility (Maroni et 
al., 2017; Gupta et al., 2015; Melocchi et al., 2015, 2018; 
Yang et al., 2018; Khaled et al., 2015a). For example gel 
barrier formation delayed solvent penetration for two 
hours and rupture of the shell for another hour in one 
study. Multi-drug devices reduce polypharmacy and 
API interactions, (Maroni et al., 2017) as one tablet can 
treat an entire condition. For example a tablet with 
three slow release compartments containing 
pravastatin, atenolol and ramipril and immediate 
release compartments containing aspirin and 
hydrochlorothiazide, known as the Polycap, is used to 
treat cardiovascular disease (Khaled et al., 2015a). For 
diabetes with hypertension a caplet has been 
produced with two slow release compartments 
containing nifedipine and glipizide. An osmotic 
pump containing captopril is also incorporated to 
provide zero order release, thus enhancing plasma 
level control throughout the day (Khaled et al., 2015b). 
Dual-compartmental dosage units for Tuberculosis 
treatment reduced interactions and allowed 
maximum absorption by immediate rifampicin 
release from the unsealed compartment into the 
stomach and delayed isoniazid release from the sealed 
compartment into the small intestine. When 
compared to in vitro testing, API release was slower 
in rats, possibly due to their low fluid volume. 
However humans have a higher fluid volume and in 
general in vivo and in vitro release correlated. Sealing 
affected in vitro release but did not appear to slow 
release in vivo possibly because of mechanical 
stimulation causing de-capping or faster dissolution, 
therefore more in vivo studies are necessary (Genina 
et al., 2017).  
Multiple-release caplets can be produced by 
embedding one caplet within a larger caplet 
(DuoCaplet). Drug release was manipulated by the 
site of API incorporation, and the lag time depended 
on external layer thickness. Longer lag times occurred 
with lower drug loads due to slower erosion-
dissolution of the external layer. A problem was 
insufficient bilayer hardness and bonding leading to 
layer disruption (Goyanes et al., 2015d), and 
unsatisfactory reproducibility due to resolution 
(Genina et al., 2017) and material expansion (Maroni 
et al., 2017; Gupta et al., 2015; Melocchi et al., 2015). 
This can be overcome by adjustment of the gap 
between the two compartments, the amount of 
plasticiser added and extrusion speed (Maroni et al., 
2017; Gupta et al., 2015). Drug load was also slightly 
less than optimal but due to loss of powder rather 
than degradation (Maroni et al., 2017). Acceptability 
of ‘polypills’ must be considered due to their size, as 
well as cost to the National Health Service. Doses of 
each API must be tailored for the individual and not 
supplied at a fixed amount. Also, regulatory approval 
has not been fully researched yet. 
Quick Response (QR) codes containing the API can be 
inkjet-printed onto an ODT which can be read by a 
smartphone using a scanning app that will detail the 
API, dose, patient name, administration code, 
expiration date and manufacturer batch identification 
code. It is hoped that this could prevent people taking 
the wrong medicine and counterfeit medicines 
(Edinger et al., 2018; Wickstrm et al., 2017). However 
the practicality of this idea is debatable because the 
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QR code integrity must be maintained upon storage 
and handling. 
An interesting development is an easy to use and 
inexpensive portable 3D printing system which 
allows pathogen incubation and can print and test 
antibiotics to direct treatment (Glatzel et al., 2016). 
Therefore it is clear that the 3D printing of oral dosage 
forms is being widely researched and has the potential 
for success. 
Topical Delivery Applications 
Only a few original research articles related to topical 
drug delivery was found. A review article was also 
discovered which suggests that either the search 
terms did not target topical delivery systems, or the 
search engines do not store many of these articles. 
However it is clear that research into the 3D printing 
of topical delivery systems is limited, possibly 
because oral dosage forms are the current focus.  
IP and SLA coat microneedle surfaces, for example 
with insulin and chemotherapy, print moulds that 
microneedles are cast in and print microneedles for 
controlled API release dictated by biodegradation. 
The first method for producing microneedles by 
Drop-on-solid (DOS) (also known as binder jetting) 
strategies was patented in 2012. Bio-compatible 
polymers used include PVA and PLA. Chitosan and 
collagen have potential use because chitosan is stable 
in a neutral environment, soluble in acidic 
environments and mucoadhesive, and collagen can be 
bio-printed as a hydrogel which can be used topically. 
Microneedles that administer vaccines are being 
explored, which would reduce pathogen 
transmission, patient discomfort and cost. A current 
problem is the limited number of biomaterials with a 
suitable viscosity at certain temperatures that are not 
photo-sensitive or degraded during printing and are 
suitable for bending (Economidou et al., 2018). 
However, biodegradable microneedle patches using 
PLA have been 3D printed by FDM. Resolution was 
significantly improved using a ‘post fabrication 
chemical etching programme’ which produced needle 
tip sizes in the range of 1 to 55 micrometres. The 
degradability of PLA can be used to control API 
release (Luzuriaga et al., 2018), thus showing the 
potential for success in this area.   
One research article discovered compared FDM to 
SLA for the 3D printing of anti-acne devices, either as 
a patch or scaffold that has been tailored to the 
person’s nose using 3D scanning. FDM used flexible 
polymers in the hope of producing comfortable 
devices. However NinjaFlex, a thermoplastic 
polyurethane polymer, produced a brittle filament 
that could not be printed. PCL and Flexible 
environmentally friendly (Flex Eco) PLA filaments 
were printed, although SLA was more successful 
because it enabled faster drug dissolution, higher 
resolution and greater drug loading due to the 
absence of heat (Goyanes et al., 2016a).  
Similarly, 3D scanning and printing have been used to 
customise the shape and size of wound dressings for 
a specific patient. Silver and copper wound dressings 
showed the best antibacterial properties. The wound 
healing process can be enhanced by a fast release 
within 24 hours, followed by slow release over 72 
hours (Muwaffak et al., 2017), thus potentially 
reducing the need for systemic antibiotics and 
therefore the threat of antibiotic resistance. 
There is potential for 3D printing to produce devices 
specifically tailored to individuals which should 
increase treatment efficacy, particularly as one of the 
main problems with topical delivery is API 
penetration. However it appears that the 3D printing 
of topical delivery systems requires much more 
development. 
Implants 
3D printed implants provide modified API release 
(Costa et al., 2015; Boetker et al., 2016; Min et al., 2015; 
Varan et al., 2017), flexible dosing and precision 
medicine using multiple geometries. EVA is used for 
the modified release of indomethacin from an Intra-
uterine Devices (IUD) and subcutaneous rods (Genina 
et al., 2016), PCL prints an IUD for indomethacin and 
contraceptive hormone release, and PLA prints disks 
for indomethacin (Kempin et al., 2017), nitrofurantoin 
(Boetker et al., 2016), gentamicin and methotrexate 
(Weisman et al., 2015) release as well as pessaries 
(Tappa et al., 2017). 
Pharmaceutical and structural treatments are 
combined, for example Boetker et al., 2016 created 
implants made from PLA loaded with nitrofurantoin 
for bone regeneration and infection prevention (Deng 
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et al., 2017), thus reducing transplant need (Nale and 
Kalbande, 2015). Polyether ether ketone (PEEK) 
scaffolds coated with silver nanoparticles are also 
used for this purpose, with a lower elastic modulus 
than titanium alloys that are closer to natural bone 
minimising implant rejection (Deng et al., 2017). 
Dexamethasone has also been successful in promoting 
bone formation because of its high stability and low 
cost, however it cannot be used at concentrations 
above 1000 nanomolar and for prolonged treatment 
due to bone loss and osteoporosis (Costa et al., 2015). 
Implants have also been designed to release isoniazid 
and rifampicin for the treatment of osteoarticular 
tuberculosis. Compared to oral formulations, liver 
and renal damage is eliminated as well as the need for 
frequent dosing.  Studies in rabbits showed that both 
APIs remained above the Minimum Inhibitory 
Concentration (MIC) for more than eight weeks, 
however due to its porous structure the implant was 
degraded in three months (Min et al., 2015), thus use 
is limited to a certain timeframe.  
Implants can be used for anti-infective purposes. For 
example nitrofurantoin was incorporated into PLA 
with the potential to produce catheters that prevent 
infection (Sandler et al., 2014). Also, paclitaxel and 
cidofovir were printed onto mucoadhesive films by IP 
for the local treatment of cervical cancer as a result of 
human papillomavirus infection. The poor solubility 
of paclitaxel is overcome by including it within 
cyclodextrin complexes and the release of cidofovir is 
controlled by encapsulation on PCL nanoparticles 
(Varan et al., 2017). 
Lattices can be coated with functional groups 
enabling the attachment of T cells for immunotherapy 
and also facilitating stable lentiviral gene delivery. 
However this process needs to be simplified and 
scaled up (Delalat et al., 2017).  
The 3D printing of oil-in-water emulsions into soft 
materials with multiphase architectures allows site-
specific incorporation of hydrophilic and 
hydrophobic compounds. When stabilised by 
chitosan-modified silica nanoparticles the resultant 
ink has high yield stress, storage modulus and elastic 
recovery (Sommer et al., 2017). 
Photo- and mechanochromic structures can be 3D 
printed, such as those containing spiropyran which 
changes colour on activation by mechanical force. 
Selective activation of different regions can be 
obtained by using two different responsive 
spiropyrans. These can be used as force sensors and 
scaffolds for small molecule release (Peterson et al., 
2015). 
Drug release must be considered when applying the 
implant to treatment. A burst phase tends to be 
experienced at first, followed by a more controlled 
release (Kempin et al., 2017; Sandler et al., 2014). 
However microparticles and nanoparticles are used to 
delay API release (Iwanaga et al., 2013; Varan et al., 
2017). Drug loading is relative to implant use. For 
example Water et al., 2015 showed that even a low 
nitrofurantoin load of 10% was more effective at 
reducing bacterial growth than a placebo implant. 
Higher drug loading may be more effective, but care 
must be taken not to increase bacterial resistance and 
side effects. To control release of the API a balance 
between porosity, erosion rate and API loading is 
necessary (Sommer et al., 2017; Costa et al., 2015). This 
can be achieved by fine-tuning scaffold architecture 
using 3D printing and water soluble excipients such 
as hydroxypropyl methylcellulose (HPMC) can be 
incorporated to form pores. Increasing the 
concentration of HPMC increases pore formation and 
drug release rates, therefore API release can be 
controlled by manipulating HPMC concentration 
(Boetker et al., 2016).  
Using biodegradable polymers such as PLA, EVA and 
PCL prevents problems with permanent implants 
such as surgery for removal, host immune responses, 
infection and toxicity (Boetker et al., 2016; Weisman et 
al., 2015). However, pure polylactic-co-glycolic acid 
(PLGA) and other biocompatible polymers cause a 
significant decrease in pH due to acidic degradation 
products, which could cause drug resistance. 
Mesoporous silica based materials are better for 
localised and controlled drug delivery without pH 
decreases (Min et al., 2015). 
Increasing shear forces during extrusion, premixing of 
API and excipients or feeding excipients such as 
hydroxyapatite nanoparticles with osteoconductive 
properties as a suspension was shown to improve API 
dispersant size and homogeneity by fractioning large 
agglomerates (Water et al., 2015). Adding silicone to 
the polymer enabled more efficient extrusion and a 
consistent dispersion of the API. A vortex can also be 
  https://doi.org/10.5920/bjpharm.2018.XX 
Hampshire and Russell (2018) BJPharm, Vol(No), pp  13 
used to suspend additives evenly on the surface 
(Weisman et al., 2015). 
Magnetic resonance imaging and computerised 
tomography can print the appropriately shaped 
implant for the patient (Kempin et al., 2017) which can 
reduce problems such as pelvic inflammatory disease 
and uterine perforations in the case of IUDs. 3D 
printing also enables the API dose to be tailored to the 
individual for optimum efficacy (Tappa et al., 2017). 
Problems with 3D printed implants include 
incomplete API release, which was encountered by 
Boetker et al., 2016 when insufficient HPMC was 
added (Water et al., 2015; Boetker et al., 2016) which 
proves the importance of water soluble polymers. 
Further problems include insufficient drug loading 
which can be caused by API loss during printing. This 
could be prevented by premixing the API and 
polymer (Boetker et al., 2016), however this is difficult 
when the API is supplied as a powder and the 
polymer is a filament in FDM. Consequently further 
development in FDM 3D printing is necessary to 
allow the direct feeding of different starting materials 
into the 3D printer. 
Research in this area is developing, although 
improvements are necessary to balance optimal drug 
loading with the prevention of side effects, toxicity 
and the creation of bacterial resistance. Elution 
profiles also need to be fully understood. Future 
development could look at incorporating further 
immunosuppressors, antibiotics, anti-inflammatories 
and drugs that stimulate cellular proliferation into 
implants. 
Hydrogels 
Hydrogels can be used as implants, scaffolds to grow 
tissue or for drug testing. They can act as reservoirs 
and deliver specific APIs to a target site but it is also 
possible to design multilayer and injectable 
hydrogels. By varying the sequence of stacking it is 
possible to tailor hydrogel geometry, porosity and 
mechanical strength, where decreased scaffold 
stiffness occurs with increased porosity (Gloria et al., 
2016). Hydrogel stiffness and permeability can also be 
manipulated by chemical modification of gel-forming 
polymers (Raman et al., 2016). Hydrogels allow 
nutrient diffusion to cells and characteristics such as 
spatial control and viscoelastic properties can be 
tailored to mimic different tissues (Han et al., 2016; 
Ersumo et al., 2016). Storage modulus, yield stress, 
and viscosity increase with polymer concentration, for 
example up to a methacrylated hyaluronic acid 
(HAMA) content of 0.75% w/w, but decrease above 
this. Crosslinkable polysaccharides such as 
hyaluronic acid improve mechanical properties and 
degradation profiles. More pronounced 
thermosensitivity, shear thinning and yield stress 
improve the printability of hydrogels (Abbadessa et 
al., 2017). Hydrocolloid polymers are used as they are 
safe and drug release is controlled by limiting 
diffusion rate through the polymer. Hydrogels made 
from hyaluronic acids, alginate and 
hydroxyethylcellulose (HEC) are biocompatible and 
show good printability, with PCL added for strength 
(Andersen et al., 2013). 
Drug release is via diffusion through the swollen 
matrix, so increasing the water content enables faster 
swelling and release rates (Wang et al., 2017; Han et 
al., 2016; Boetker et al., 2016; Yang et al., 2018). Release 
rates are also controlled by surface area to volume 
ratio and the structure can be manipulated (Wang et 
al., 2017; Han et al., 2016; Boetker et al., 2016) to enable 
faster API release than hydrogels prepared using 
traditional methods (Wang et al., 2017). Humidity 
affects pore formation as smaller pores are formed 
and release rate increases when evaporation rate 
increases (Raman et al., 2016; Han et al., 2016). 
Crosslinkable components act as pore-forming agents, 
therefore increasing their concentration leads to faster 
water uptake and drug release. Higher viscosity 
hydrogels exhibit slower release rates and resin 
components can be altered to tailor release profiles 
(Martinez et al., 2017). Complex release profiles can 
also be planned by tuning hydrophobic and 
hydrophilic polymer concentrations (Abbadessa et al., 
2017). 
APIs are loaded by immersing the hydrogel in an 
aqueous solution so that it swells and the API enters 
by diffusion. Printing pre-swollen hydrogels enables 
entrapment of a known and high quantity of drug, 
encapsulation of poorly soluble drugs and ensures 
sufficient water for solubilisation and drug release 
(Martinez et al., 2017; Wang et al., 2017).  A high water 
content is often required for appropriate printing 
viscosity and surface tension (Han et al., 2016). 
However, water contents above 20% can impede the 
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reproducibility of printing as water dilutes the resin 
and reduces viscosity (Martinez et al., 2017; Bootsma 
et al., 2017).  
Coupling SLA with a chemical conjugation technique 
enables spatial segregation and localisation of the API 
within different areas of the hydrogel, which increases 
the API release rate and prevents interactions (Raman 
et al., 2016). SLA also enables the fabrication of pre-
swollen hydrogels such as ibuprofen-loaded 
hydrogels of cross-linked PEGDA. The degree of 
cross-linking is influenced by the ratio of diluent to 
resin and the concentration of cross-linking agents so 
that the hydrogels are capable of tuneable API release. 
(Martinez et al., 2017). Keratin is biodegradable, can 
self-assemble, has sufficient compressive moduli, 
provides adequate cell support and is made from the 
renewable resource of human hair. Sufficient uptake, 
swelling properties, and the ability to modify cross-
linking density by modifying keratin content has 
made keratin suitable for the SLA printing of 
hydrogels used in tissue engineering and regenerative 
medicine (Placone et al., 2017; Bertassoni et al., 2014).  
IP is often used for tissue bioprinting, requiring a 
limited number of materials including natural 
proteins, polysaccharides such as agar, fibrin, 
hyaluronic acid, gelatine, and collagen. Direct write 
printing allows greater control of macroscale 
structures and more straightforward bioprinting, 
however it is limited by viscosity and concentration 
(Bertassoni et al., 2014).  
Shape memory hydrogels are printed using calcium 
cross-linked alginate. They form a reversible structure 
and have a high recovery; mechanical properties are 
restored in thirty minutes. The API is released during 
deformation so the hydrogel is useful for drug 
delivery in surgery. The use of alginate also promotes 
cell growth as it is a polysaccharide, and it does not 
degrade in vitro so is good for short term implantation 
(Wang et al., 2017). However drug leaching often 
occurs, so a shear thinning viscosity modifier such as 
HEC is often added to aid printing (Andersen et al., 
2013). 
Multilayer biodegradable conducting hydrogels can 
be produced for tissue engineering using graphene 
nanosheets in a chitosan host polymer which 
improves cell adhesion, proliferation and spreading 
(Sayyar et al., 2017). 
Hydrogels can be printed containing small interfering 
ribonucleic acids (siRNAs) in a spatially controlled 
manner. Structures are seeded with mesenchymal 
stem cells so that selected siRNAs are delivered to 
cells and induce specific and localised gene silencing. 
Deposition of active molecules such as siRNAs, 
plasmid deoxyribonucleic acid (DNA) and viral 
vectors into hydrogels causes programmed 
differentiation of seeded stem cells. This can be used 
to create individualised tissues to fit patient data or 
used as a screening platform for different APIs 
(Andersen et al., 2013).   
Current problems with hydrogels are insufficient 
mechanical strength and limited biocompatible 
materials (Andersen et al., 2013).  A second polymer 
can be incorporated to form an interpenetrating cross-
linked polymer network which improves mechanical 
strength and enables tuneable viscoelastic properties. 
For example acrylamide and hydroxyethyl acrylate 
(HEA) can form hydrogen bonds to create hydrogels 
with a higher elastic modulus (Bootsma et al., 2017).  
Research in this area is limited and could be improved 
with a better understanding of hydrogel behaviour, so 
that mechanical properties can be manipulated 
(Ersumo et al., 2016).  It is hopeful that the use of 
hydrogels as API-eluting devices will develop in the 
future with a better understanding of excipient effect 
on hydrogel printing. 
CONCLUSIONS 
3D printing is a rapidly developing area of interest. It 
was concluded after analysis of 70 articles that the 
current main trends within 3D printing and drug 
development are the areas of oral dosage forms, 
implants, hydrogels and topical delivery systems. 
Oral dosage forms are currently the most widely 
researched area. Research in all areas is increasing, 
however substantial future development is required. 
3D printing has the potential to offer on-demand 
medication production anywhere and improve 
medication efficacy by printing extremely valuable 
personalised dosage forms. 
There have been successes, including the first 3D 
printed ODT, however current drawbacks include the 
limited availability of non-toxic excipients, polymers 
and printing processes that do not cause API 
degradation. Unfortunately there is currently very 
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little in vivo testing of 3D printed formulations, 
therefore it is difficult to determine their efficacy in 
man.   
Future evaluation should be aimed at a thorough 
analysis of one area established within the trends, for 
example by studying dissolution data for all of the 
current 3D printed oral dosage forms. The data 
collected is likely to be homogenous in such instance 
and therefore meta-analysis could be completed, 
providing a high standard of assessment. This data 
could be compared to dosage forms produced by 
traditional methods to conclude whether the 3D 
printing of medication is advantageous. Further 
developments require the completion of extensive in 
vivo studies and the production of more polymers 
and excipients that are biocompatible. However it is 
clear that 3D printing will improve the accessibility, 
efficacy and cost effectiveness of drug manufacture.  
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